Allosteric inhibition of IgE-FcεRI interactions by simultaneous targeting of IgE F(ab')2 epitopes.


Journal

Communications biology
ISSN: 2399-3642
Titre abrégé: Commun Biol
Pays: England
ID NLM: 101719179

Informations de publication

Date de publication:
23 Aug 2024
Historique:
received: 12 06 2023
accepted: 24 07 2024
medline: 24 8 2024
pubmed: 24 8 2024
entrez: 23 8 2024
Statut: epublish

Résumé

Immunoglobulin E (IgE) plays pivotal roles in allergic diseases through interaction with a high-affinity receptor (FcεRI). We established that Fab fragments of anti-IgE antibodies (HMK-12 Fab) rapidly dissociate preformed IgE-FcεRI complexes in a temperature-dependent manner and inhibit IgE-mediated anaphylactic reactions, even after allergen challenge. X-ray crystallographic studies revealed that HMK-12 Fab interacts with each of two equivalent epitopes on the Cε2 homodimer domain involved in IgE F(ab')2. Consequently, HMK-12 Fab-mediated targeting of Cε2 reduced the binding affinity of Fc domains and resulted in rapid removal of IgE from the receptor complex. This unexpected finding of allosteric inhibition of IgE-FcεRI interactions by simultaneous targeting of two epitope sites on the Cε2 homodimer domain of IgE F(ab')2 may have implications for the development of novel therapies for allergic disease.

Identifiants

pubmed: 39179708
doi: 10.1038/s42003-024-06633-4
pii: 10.1038/s42003-024-06633-4
doi:

Substances chimiques

Immunoglobulin E 37341-29-0
Receptors, IgE 0
Immunoglobulin Fab Fragments 0
Epitopes 0
anti-IgE antibodies 0
Antibodies, Anti-Idiotypic 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1042

Subventions

Organisme : Japan Society for the Promotion of Science London (JSPS London)
ID : 21K08447
Organisme : Japan Agency for Medical Research and Development (AMED)
ID : JP21am0101070

Informations de copyright

© 2024. The Author(s).

Références

Prescott, S. L. et al. A global survey of changing patterns of food allergy burden in children. World Allergy Organ J. 6, 21 (2013).
pubmed: 24304599 pmcid: 3879010 doi: 10.1186/1939-4551-6-21
Ishizaka, K., Ishizaka, T. & Hornbrook, M. M. Physico-chemical properties of human reaginic antibody. IV. Presence of a unique immunoglobulin as a carrier of reaginic activity. J. Immunol. 97, 75–85 (1966).
pubmed: 4162440 doi: 10.4049/jimmunol.97.1.75
Ishizaka, K. & Ishizaka, T. Identification of IgE. J. Allergy Clin. Immunol. 137, 1646–1650 (2016).
pubmed: 27090936 doi: 10.1016/j.jaci.2015.12.1343
Gould, H. J. et al. The biology of IGE and the basis of allergic disease. Annu. Rev. Immunol. 21, 579–628 (2003).
pubmed: 12500981 doi: 10.1146/annurev.immunol.21.120601.141103
Turner, P. J. et al. Increase in anaphylaxis-related hospitalizations but no increase in fatalities: an analysis of United Kingdom national anaphylaxis data, 1992-2012. J. Allergy Clin. Immunol. 135, 956–963 (2015).
pubmed: 25468198 pmcid: 4382330 doi: 10.1016/j.jaci.2014.10.021
Jerschow, E., Lin, R. Y., Scaperotti, M. M. & McGinn, A. P. Fatal anaphylaxis in the United States, 1999-2010: temporal patterns and demographic associations. J. Allergy Clin. Immunol. 134, 1318–1328 (2014).
pubmed: 25280385 pmcid: 4260987 doi: 10.1016/j.jaci.2014.08.018
Sanjuan, M. A., Sagar, D. & Kolbeck, R. Role of IgE in autoimmunity. J. Allergy Clin. Immunol. 137, 1651–1661 (2016).
pubmed: 27264000 doi: 10.1016/j.jaci.2016.04.007
Holowka, D. & Baird, B. Structural studies on the membrane-bound immunoglobulin E-receptor complex. 1. Characterization of large plasma membrane vesicles from rat basophilic leukemia cells and insertion of amphipathic fluorescent probes. Biochemistry 22, 3466–3474 (1983).
pubmed: 6225455 doi: 10.1021/bi00283a025
Zheng, Y., Shopes, B., Holowka, D. & Baird, B. Conformations of IgE bound to its receptor Fc epsilon RI and in solution. Biochemistry 30, 9125–9132 (1991).
pubmed: 1832555 doi: 10.1021/bi00102a002
Drinkwater, N. et al. Human immunoglobulin E flexes between acutely bent and extended conformations. Nat. Struct. Mol. Biol. 21, 397–404 (2014).
pubmed: 24632569 pmcid: 3977038 doi: 10.1038/nsmb.2795
Beavil, A. J., Young, R. J., Sutton, B. J. & Perkins, S. J. Bent domain structure of recombinant human IgE-Fc in solution by X-ray and neutron scattering in conjunction with an automated curve fitting procedure. Biochemistry 34, 14449–14461 (1995).
pubmed: 7578050 doi: 10.1021/bi00044a023
Wan, T. et al. The crystal structure of IgE Fc reveals an asymmetrically bent conformation. Nat. Immunol. 3, 681–686 (2002).
pubmed: 12068291 doi: 10.1038/ni811
Ishizaka, T. & Ishizaka, K. Activation of mast cells for mediator release through IgE receptors. Prog. Allergy 34, 188–235 (1984).
pubmed: 6199797
Serafin, W. E. & Austen, K. F. Mediators of immediate hypersensitivity reactions. New Engl. J. Med. 317, 30–34 (1987).
pubmed: 2438554 doi: 10.1056/NEJM198707023170106
Metzger, H. The receptor with high affinity for IgE. Immunol. Rev. 125, 37–48 (1992).
pubmed: 1532373 doi: 10.1111/j.1600-065X.1992.tb00624.x
Zellweger, F. & Eggel, A. IgE-associated allergic disorders: recent advances in etiology, diagnosis, and treatment. Allergy 71, 1652–1661 (2016).
pubmed: 27709638 doi: 10.1111/all.13059
Stokes, J. R. & Casale, T. B. The use of anti-IgE therapy beyond allergic asthma. J. Allergy Clin. Immunol. Pr. 3, 162–166 (2015).
doi: 10.1016/j.jaip.2014.10.010
Kawakami, T. & Blank, U. From IgE to Omalizumab. J. Immunol. 197, 4187–4192 (2016).
pubmed: 27864548 doi: 10.4049/jimmunol.1601476
Chipps, B. E. et al. Omalizumab in children with uncontrolled allergic asthma: Review of clinical trial and real-world experience. J. Allergy Clin. Immunol. 139, 1431–1444 (2017).
pubmed: 28477722 doi: 10.1016/j.jaci.2017.03.002
MacGinnitie, A. J. et al. Omalizumab facilitates rapid oral desensitization for peanut allergy. J. Allergy Clin. Immunol. 139, 873–881 (2017).
pubmed: 27609658 doi: 10.1016/j.jaci.2016.08.010
Lawrence, M. G. et al. Half-life of IgE in serum and skin: consequences for anti-IgE therapy in patients with allergic disease. J. Allergy Clin. Immunol. 139, 422–428 (2017).
pubmed: 27496596 doi: 10.1016/j.jaci.2016.04.056
Presta, L. G. et al. Humanization of an antibody directed against IgE. J. Immunol. 151, 2623–2632 (1993).
pubmed: 8360482 doi: 10.4049/jimmunol.151.5.2623
Jardieu, P. M. & Fick, R. B. Jr. IgE inhibition as a therapy for allergic disease. Int. Arch. Allergy Immunol. 118, 112–115 (1999).
pubmed: 10224354 doi: 10.1159/000024043
Boulet, L. P. et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am. J. Respir. Crit. Care Med. 155, 1835–1840 (1997).
pubmed: 9196083 doi: 10.1164/ajrccm.155.6.9196083
Maurer, M. et al. Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence. J. Allergy Clin. Immunol. 141, 638–649 (2018).
pubmed: 28751232 doi: 10.1016/j.jaci.2017.06.032
Hirano, T. et al. The Fab fragment of anti-IgE Cε2 domain prevents allergic reactions through interacting with IgE-FcεRIα complex on rat mast cells. Sci. Rep. 8, 14237 (2018).
pubmed: 30250145 pmcid: 6155129 doi: 10.1038/s41598-018-32200-z
McDonnell, J. M. et al. The structure of the IgE Cepsilon2 domain and its role in stabilizing the complex with its high-affinity receptor FcepsilonRIalpha. Nat. Struct. Biol. 8, 437–441 (2001).
pubmed: 11323720 doi: 10.1038/87603
Eggel, A. et al. Accelerated dissociation of IgE-FcεRI complexes by disruptive inhibitors actively desensitizes allergic effector cells. J. Allergy Clin. Immunol. 133, 1709–1719 (2014).
pubmed: 24642143 pmcid: 4083100 doi: 10.1016/j.jaci.2014.02.005
Davies, A. M. et al. Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumab. J. Biol. Chem. 292, 9975–9987 (2017).
pubmed: 28438838 pmcid: 5473249 doi: 10.1074/jbc.M117.776476
Pennington, L. F. et al. Structure-guided design of ultrapotent disruptive IgE inhibitors to rapidly terminate acute allergic reactions. J. Allergy Clin. Immunol. 148, 1049–1060 (2021).
pubmed: 33991582 pmcid: 8502201 doi: 10.1016/j.jaci.2021.03.050
Laffer, S. et al. A high-affinity monoclonal anti-IgE antibody for depletion of IgE and IgE-bearing cells. Allergy 63, 695–702 (2008).
pubmed: 18325077 doi: 10.1111/j.1398-9995.2008.01664.x
Jabs, F. et al. Trapping IgE in a closed conformation by mimicking CD23 binding prevents and disrupts FcεRI interaction. Nat. Commun. 9, 7 (2018).
pubmed: 29295972 pmcid: 5750235 doi: 10.1038/s41467-017-02312-7
McDonnell, J. M., Dhaliwal, B., Sutton, B. J. & Gould, H. J. IgE, IgE receptors and anti-IgE biologics: protein structures and mechanisms of action. Annu. Rev. Immunol. 41, 255–275 (2023).
pubmed: 36737596 doi: 10.1146/annurev-immunol-061020-053712
Miyajima, H., Watanabe, N., Ovary, Z., Okumura, K. & Hirano, T. Rat monoclonal anti-murine IgE antibody removes IgE molecules already bound to mast cells or basophilic leukemia cells, resulting in the inhibition of systemic anaphylaxis and passive cutaneous anaphylaxis. Int. Arch. Allergy Immunol. 128, 24–32 (2002).
pubmed: 12037398 doi: 10.1159/000058000
Hirano, T. et al. Studies on murine IgE with monoclonal antibodies. I. Characterization of rat monoclonal anti-IgE antibodies and the use of these antibodies for determinations of serum IgE levels and for anaphylactic reactions. Int. Arch. Allergy Appl Immunol. 85, 47–54 (1988).
pubmed: 3257463 doi: 10.1159/000234473
Jensen, R. K. et al. Structure of intact IgE and the mechanism of ligelizumab revealed by electron microscopy. Allergy 75, 1956–1965 (2020).
pubmed: 32037590 doi: 10.1111/all.14222
Krissinel, E. & Henrick, K. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372, 774–797 (2007).
pubmed: 17681537 doi: 10.1016/j.jmb.2007.05.022
Metzger, H. Fc receptors and membrane immunoglobulin. Curr. Opin. Immunol. 3, 40–46 (1991).
pubmed: 1828949 doi: 10.1016/0952-7915(91)90074-B
Ravetch, J. V. & Kinet, J. P. Fc receptors. Annu. Rev. Immunol. 9, 457–492 (1991).
pubmed: 1910686 doi: 10.1146/annurev.iy.09.040191.002325
Guntern, P. & Eggel, A. Past, present, and future of anti-IgE biologics. Allergy 75, 2491–2502 (2020).
pubmed: 32249957 doi: 10.1111/all.14308
Holdom, M. D. et al. Conformational changes in IgE contribute to its uniquely slow dissociation rate from receptor FcɛRI. Nat. Struct. Mol. Biol. 18, 571–576 (2011).
pubmed: 21516097 pmcid: 3357048 doi: 10.1038/nsmb.2044
Garman, S. C., Wurzburg, B. A., Tarchevskaya, S. S., Kinet, J. P. & Jardetzky, T. SStructure of the Fc fragment of human IgE bound to its high-affinity receptor Fc epsilon RI alpha. Nature 406, 259–266 (2000).
pubmed: 10917520 doi: 10.1038/35018500
Ovary, Z., Caiazza, S. S. & Kojima, S. PCA reactions with mouse antibodies in mice and rats. Int. Arch. Allergy Appl. Immunol. 48, 16–21 (1975).
pubmed: 1116878 doi: 10.1159/000231289
Usui, M. et al. Construction of a monoclonal antibody against Igh-7a. Immunogenetics 37, 301–304 (1993).
pubmed: 8420839 doi: 10.1007/BF00187459
Katayama, S., Shionoya, H. & Ohtake, S. A new method for extraction of extravasated dye in the skin and the influence of fasting stress on passive cutaneous anaphylaxis in guinea pigs and rats. Microbiol. Immunol. 22, 89–101 (1978).
pubmed: 27704 doi: 10.1111/j.1348-0421.1978.tb00352.x
Hirata, K. et al. ZOO: an automatic data-collection system for high-throughput structure analysis in protein microcrystallography. Acta Crystallogr. Sect. D. Struct. Biol. 75, 138–150 (2019).
doi: 10.1107/S2059798318017795
Liebschner, D. et al. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr D. Struct. Biol. 75, 861–877 (2019).
pubmed: 31588918 pmcid: 6778852 doi: 10.1107/S2059798319011471
Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. Sect. D. Biol. Crystallogr. 67, 235–242 (2011).
doi: 10.1107/S0907444910045749
Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D. Biol. Crystallogr. 66, 213–221 (2010).
pubmed: 20124702 pmcid: 2815670 doi: 10.1107/S0907444909052925
Martin, A. C. R. Protein sequence and structure analysis of antibody variable domains. In Antibody Engineering. Springer Protocols Handbooks (eds Kontermann, R. & Dübel, S.) 33–51 (Springer, Berlin, Heidelberg, 2010).

Auteurs

Takao Hirano (T)

Department of Hematology, Juntendo University Nerima Hospital, Nerima-ku, Tokyo, Japan. thirano@juntendo.ac.jp.

Akemi Koyanagi (A)

Laboratory of Cell Biology, Biomedical Research Core Facilities, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan.

Hideo Ago (H)

Advanced Photon Technology Division, RIKEN SPring-8 Center, Sayo, Hyogo, Japan.

Masaki Yamamoto (M)

Advanced Photon Technology Division, RIKEN SPring-8 Center, Sayo, Hyogo, Japan.

Jiro Kitaura (J)

Atopy Research Center, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan.
Department of Science of Allergy and Inflammation, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan.

Masataka Kasai (M)

Atopy Research Center, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan.

Ko Okumura (K)

Atopy Research Center, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH